QSAR : Quantitative Structure-Activity Relationships in Drug Design , Proceedings of the 7th European Symposium on QSAR held in Interlaken, Switzerland, September 5 - 9 1988
QSAR methods and stereoselectivity in action; QSAR, a European viewpoint; Consequences of the Hansch Paradigm, part 2; Comparative structure-activity relationships; Some problems of the interpretation of receptorologic data in QSAR work; Quantitative and explicit structure-time-activity relations; QSAR analysis of chiral compounds including racemates; Surface area and hydrophobicity of small molecules; Increasing the accuracy of computer calculated log P (Oct/Water) values; Titrations in water-saturated octanol, a guide to partition coefficients of ion pairs and receptor-site interactions; Quantitative structure affinity relationships in a series of alpha-2 adrenergic amines using the molecular lipophilicity potential; Lipophilicity and conformational behavior of substituted Xanthines; Determination of the partition coefficients of adamantyl derivatives by reversed phase TLC and HPLC; Comparison between measured and calculated partition coefficients of beta-receptor antagonists; Benzenesulfonamide inhibitors of carbonic anhydrase, study of their hydrophobicity by RPLC; Partition coefficients of diazines; Lipophilicity of a series of cytostatic aziridinyl quinones; QSAR parameters a la carte from computer chemistry; CISOC-SARSS, a versatile structure-activity relationship study system; DESBASE, a multiparameter substituent database; An index of flexibility from molecular shape descriptors; A new type of information index and its use; QSAR and multivariate data analysis of the interaction of amphiphilic drugs with phospholipids; Multivariate data analyses of QSAR parameters; Principal properties of aromatic substituents; Multivariate parametrization of coded and non-coded amino acids by thin layer chromatography; Response surfaces for modelling biological activities by principal properties of substituents, The Carso Procedure; Analogy in computer-assisted design; Automatic knowledge base building for the organic synthesis design program (SECS); Molecular shape analysis of structure-activity tables; Recent advances in comparative molecular field analysis (CoMFA); Molecular similarity, a basis for designing drug screening programs; Implementing drug screening programs using molecular similarity methods; Strategies in drug design based on 3D structures of ligands; Logic-based methods for drug design; The use of 3D modelling databases for identifying structure-activity relationships; QSAR oriented computer representation of chemical compounds used in CISOC-SARSS; Discovering activity determinants, graphics and a related probability; DARC/PELCO success in anticholinergic research; Antineoplastic activity prediction by means of a statistical-heuristic technique; QSAR analysis of acetylcholinesterase inhibitors by use of structure similarity methods; Structural databases and computer modeling in pharmaceutical research; Computer aided peptide and protein engineering; Molecular modeling of beta-cyclodextrin drug inclusion complexes based on NMR interaction measurements; Molecular modelling of the interaction of dihydropyridine drugs with their receptors; Computer aided molecular modelling applied by the dopaminergic system; Conformational analysis of antifolates, molecular structure and enzyme binding of the 4'-COOH trimethoprim derivative; Molecular modelling of inhibitors and herbicides for photosynthetic systems; Common conformational and electronic features for nondihydropyridines calcium antagonists; Molecular electrostatic potentials, a critical assessment in QSAR and a tryptamine binding model; Beta-adrenoceptor modeling based on MEP studies; Electrostatic potential maps of enzyme inhibitors; Binding of agonists and antagonists to beta-adrenergic receptor; Why are benzocycloheptenylamines inactive as dopamine D2-receptor agonists; Mechanism based analysis of enzyme inhibitors of amide bond hydrolysis; Cholecystokinin inhibitors, a combined QSAR and molecular graphic analysis; Cyclosporine, intrinsic binding energies to interpre structure-activity relationships; Quantification of peptide bioactivities, peptide antibiotics; Peptide QSARs, PLS modelling and design in principal properties; Sweet taste receptor recognition of the conformationally flexible aldoxime molecule; Conformational study of erythromycin analogues; Conformational analysis of fenpropimorph; 3D-QSAR, towards a quantitative three dimensional description of muscarinic agonists; QSAR study in xenobiotics distribution-estimation of target organ; The structure selectivity problem in drug design with respect to antifolates; Comparative QSAR analysis in dihydropteroate synthase inhibition by sulphones, design and synthesis of some new derivatives with improved potency; Structure-activity studies of chemical carcinogens in non-congeneric sets of compounds; QSAR study of analgesic and anti-inflammatory potencies of commercially available non-steroidal anti-inflammatory drugs (NSAIDs); Use of QSAR in design of anti-inflammatory arylalkanoic acids; A QSAR study of a series of beta-carbolines; Theoretical study of the tautomerism of adenosine and formycin, functional implications; QSAR on substituted salicylamides; Structure-activity relationships of H2-receptor histamine antagonists based on quantum chemical methods; Design, synthesis, and SAR of analgesics; A Free-Wilson analysis of the calcium channel blocking activity of some dihydropyridines; On the use of 1H-NMR and 13C-NMR chemical shifts in a QSAR of benzotriazole derivatives; Statistical analysis of electronic absorption spectra of N-methylpyrazoles; The application of Free-Wilson models in spectroscopy of pyrazoles, delta-H4 1H-NMR; QSAR in olfaction, ambergris type odorants; Correlation of hydrophobicity and molecular connectivities with toxicities of chlorobenzenes to different species; Modeling environmental distribution of organic pollutants; QSARs and pesticides design; A QSAR study of Overton's tadpole data.